20:17 , Oct 5, 2018 |  BC Week In Review  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
20:14 , Oct 4, 2018 |  BC Extra  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
19:16 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Filgotinib meets in Phase III FINCH 2 study for RA

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said both doses of filgotinib met the primary and all key secondary endpoints in the Phase III FINCH 2 trial to treat rheumatoid arthritis. Filgotinib is...
22:45 , Sep 13, 2018 |  BC Week In Review  |  Financial News

Galapagos follows positive RA data with $300M round

On the heels of positive Phase III data for rheumatoid arthritis therapy filgotinib, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) raised $300 million on Sept. 13 through the sale of 2.6 million ADSs at $116.50 on NASDAQ. Morgan...
05:33 , Sep 13, 2018 |  BC Extra  |  Financial News

Galapagos follows positive RA data with $300M round

On the heels of positive Phase III data for rheumatoid arthritis therapy filgotinib, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) raised $300 million through the sale of 2.6 million ADSs at $116.50 on NASDAQ. Morgan Stanley, Citigroup, Kempen...
18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

J&J's Xarelto misses in pair of Phase III trials in acute medically ill and heart failure patients

Johnson & Johnson (NYSE:JNJ) reported that anticoagulant Xarelto rivaroxaban missed the primary endpoints in both the Phase III MARINER and COMMANDER HF trials. Data were presented at the European Society of Cardiology meeting in Munich...
12:04 , May 24, 2018 |  BioCentury  |  Finance

Chasing China

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....
22:50 , May 11, 2018 |  BioCentury  |  Finance

Watching the wave

After raising the largest ever series B round for a Chinese biotech, CStone Pharmaceuticals Co. Ltd. should have enough funding to run four pivotal cancer studies in parallel as it monitors the performance of the...
18:12 , May 11, 2018 |  BC Week In Review  |  Financial News

Chinese immuno-oncology play CStone raises $260M

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) raised on May 8 $260 million in a series B round led by new investor GIC Private. CStone said the round is the largest series B ever for a...
16:38 , May 9, 2018 |  BC Extra  |  Financial News

Chinese immuno-oncology play CStone raises $260M

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) raised $260 million in a series B round led by new investor GIC Private. CStone said the round is the largest series B ever for a Chinese biopharma. New investors...